Articles

Laughter therapy is a universal non-pharmacologic approach to reduce stress and anxiety. Laughter therapy can be used during COVID-19 pandemic as a useful supplementary therapy to reduce the mental health burden.

Using event-related potentials (ERPs) might help identify early neural changes indicative of future cognitive decline, offering an accessible and affordable alternative to other neuroimaging methods

Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological conditions including the fatal neuromuscular disease Duchenne Muscular Dystrophy (DMD). DMD is a complicated disease, with many druggable targets at the cellular and molecular level including calcium-mediated muscle degeneration; mitochondrial dysfunction; oxidative stress; inflammation; insufficient muscle regeneration and dysregulated protein and organelle maintenance. Previous investigative therapeutics tended to isolate and focus on just one of these targets and, consequently, therapeutic activity has been limited. Nuclear erythroid 2-related factor 2 (Nrf2) is a transcription factor that upregulates many cytoprotective gene products in response to oxidants and other toxic stressors. Unlike other strategies, targeted Nrf2 activation has the potential to simultaneously modulate separate pathological features of DMD to amplify therapeutic benefits. Here, we review the literature providing theoretical context for targeting Nrf2 as a disease modifying treatment against DMD.

Using China Health and Nutrition Survey data, this study employs a consistent two-step quadratic almost ideal demand system model, with addressed problems of endogeneity of total expenditure and zero shares, to estimate the food demand elasticities among adults in rural areas with regard to the different income strata.